The estimated Net Worth of Joan Winterbottom is at least $18.8 Tisíc dollars as of 13 November 2012. Joan Winterbottom owns over 1,665 units of Amicus Therapeutics Inc stock worth over $18,765 and over the last 12 years Joan sold FOLD stock worth over $0.
Joan has made over 1 trades of the Amicus Therapeutics Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently Joan bought 1,665 units of FOLD stock worth $7,559 on 13 November 2012.
The largest trade Joan's ever made was buying 1,665 units of Amicus Therapeutics Inc stock on 13 November 2012 worth over $7,559. On average, Joan trades about 333 units every 0 days since 2012. As of 13 November 2012 Joan still owns at least 1,665 units of Amicus Therapeutics Inc stock.
You can see the complete history of Joan Winterbottom stock trades at the bottom of the page.
Joan's mailing address filed with the SEC is C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY, NJ, 08512.
Over the last 17 years, insiders at Amicus Therapeutics Inc have traded over $306,740,337 worth of Amicus Therapeutics Inc stock and bought 23,821,602 units worth $176,323,212 . The most active insiders traders include Advisors Llcperceptive Life..., Peter J Barris a Plc Gsk. On average, Amicus Therapeutics Inc executives and independent directors trade stock every 10 days with the average trade being worth of $830,419. The most recent stock trade was executed by Bradley L Campbell on 3 September 2024, trading 7,500 units of FOLD stock currently worth $64,575.
amicus therapeutics is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. we have a unique set of platform technologies and medicines in development for patients living with the lysosomal storage disorders fabry disease and pompe disease and we are committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for these and other rare diseases. the needs of patients in the rare disease community are at the center of our inventive science, our commercial organization, and our clinical programs. our goal throughout all levels of the organization is to make a meaningful difference in the lives of these patients and their caregivers. several opportunities are available to join our team as we build a leading global biotechnology company focused on rare metabolic diseases. our amicus footprint spans 27 countries including our g
Amicus Therapeutics Inc executives and other stock owners filed with the SEC include: